ResMed dominates healthcare devices with innovation, recurring revenues, and market leadership. See why we believe RMD stock ...

Australian sleep health giant Resmed has locked down an exemption from Donald Trump’s sweeping trade tariffs. Resmed produces ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near-term risk from this therapy due to the higher cost and invasive surgery ...

A major Australian company has managed to secure a tariff exemption from the Trump Administration as the world waits to see ...

UBS lowered the firm’s price target on ResMed (RMD) to $285 from $290 and keeps a Buy rating on the shares.Stay Ahead of the Market: Discover ...

Australian sleep device giant ResMed has secured an exemption from Donald Trump’s global tariffs in a major win for the ...

Noise level: Our pick for the best quiet CPAP machine is the Luna G3, but you'll want to make sure that whichever model you ...

Analysts have provided ResMed with 5 ratings, resulting in a consensus rating of Outperform. The average one-year price ...

EPS of $2.37 on $1.29 billion in sales, citing strong global demand for sleep devices, plus a boost from tariff exemptions.

KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $274 from $269 on higher estimates, while keeping an Overweight ...

Resmed shares remained unmoved after hours today on third-quarter results that came in ahead of the consensus forecast.

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.